Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ARRAY BIOPHARMA INC | a06301610-k.htm |
| EX-32.1 - EXHIBIT 32.1 - ARRAY BIOPHARMA INC | a06302016ex321.htm |
| EX-31.2 - EXHIBIT 31.2 - ARRAY BIOPHARMA INC | a06302016ex312.htm |
| EX-31.1 - EXHIBIT 31.1 - ARRAY BIOPHARMA INC | a06302016ex311.htm |
| EX-10.73 - EXHIBIT 10.73 - ARRAY BIOPHARMA INC | haddockconfandinventionsag.htm |
| EX-10.72 - EXHIBIT 10.72 - ARRAY BIOPHARMA INC | haddocknoncompeteex1072.htm |
| EX-10.71 - EXHIBIT 10.71 - ARRAY BIOPHARMA INC | haddockemploymentagreement.htm |
| EX-10.7 - EXHIBIT 10.7 - ARRAY BIOPHARMA INC | comerica-thirteenthamendme.htm |
| EX-3.1 - EXHIBIT 3.1 - ARRAY BIOPHARMA INC | consolcertofincorpasrestat.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Array BioPharma Inc.:
We consent to the use of our reports dated August 19, 2016, with respect to the balance sheets of Array BioPharma Inc. as of June 30, 2016 and 2015, and the related statements of operations and comprehensive income (loss), stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended June 30, 2016, and the effectiveness of internal control over financial reporting as of June 30, 2016, incorporated by reference herein.
/s/ KPMG LLP
Boulder, Colorado
August 19, 2016